Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia

Sutacimig has potential to become a first-in-class prophylactic treatment for Glanzmann thrombasthenia, an inherited serious bleeding disorder CAMBRIDGE, Mass. and COPENHAGEN, Denmark, March 5, 2026 /PRNewswire/ -- Hemab Therapeutics, a late stage clinical biotechnology company developing...